Navigation Links
Tamaris Announces Foot and Leg Ulcers Pose Significant Health Threat
Date:1/27/2009

A new research study could redefine treatment for disease

Chicago, IL (Vocus) January 27, 2009 -- Americans are living longer, but living longer means our aging population is at greater risk for acquiring disease. For those with high cholesterol, diabetes and high blood pressure, Peripheral Artery Disease (PAD) is of particular concern.

PAD, often described as "poor circulation," is diagnosed when the large arteries of the leg narrow thereby restricting blood flow. The tissues then become starved of the blood, nutrients, and oxygen they need, and in its most advanced form, skin ulcers begin to develop. At this stage of PAD, called Critical Limb Ischemia (CLI), the health threat is serious.

The threat is so serious that it is difficult to grasp, but here are the facts: PAD at the stage of Critical Limb Ischemia presents the likelihood of amputation or even death. At this time, there are no prescription drugs available to effectively treat Critical Limb Ischemia, and there are limited treatments available that will delay or prevent amputation.

While these facts present a grim outlook, there is hope, thanks to a unique new opportunity. Robert Jeffrey, MD is currently conducting an investigational research study for PAD at the stage of Critical Limb Ischemia with foot and/or leg ulcers. It is anticipated that the investigational study medication may promote new blood vessel growth, and may delay the time to amputation and/or death.

The research study is currently seeking qualified participants. Individuals must be: 50 years of age or older with stable skin ulcers or non-infected gangrene on a foot or leg; diagnosed with Peripheral Arterial Disease (PAD) at the stage of Critical Limb Ischemia; and be unsuitable for by-pass or revascularization. Additional criteria also apply.

If you or someone you know suffers with skin ulcers due to PAD at the stage of Critical Limb Ischemia, please call us to determine eligibility at 1-888-853-4656 ... or visit our web site at www.tamarisstudy.com.

This research study is now underway throughout the United States, including the Chicago area.

Today's research touches our future ... and there is a possibility that the information obtained in this study may help in the future development of a new therapy for those who suffer from Critical Limb Ischemia with foot and/or leg ulcers. For more information, please contact Hal Coxon at (847) 919-1005 or via email at halcoxon(at)axmarketing.com.

Contact:
Hal Coxon
Axiom Accelerated Clinical Patient Recruitment
(847) 919-1005
halcoxon(at)axmarketing.com
www.tamarisstudy.com.

###

Read the full story at http://www.prweb.com/releases/Peripheral_Artery_Disease/Critical_Limb_Ischemia/prweb1903004.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular line ... Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been in ... trusted, well-respected brand reliant on the healing properties of plants, a proven science ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... to serve as strategic adviser to the animal healthcare division of Sonoma ... Bridge Animal Referral Center (BARC) in Edmonds, Washington, which specializes in compassionate ...
(Date:9/19/2017)... ... , ... Premiere Long Island dental office Gold Coast Smiles is pleased to ... dentists in America under age 40 by Incisal Edge magazine. , Incisal Edge ... the best 40 dentists under the age of 40 renowned for medical innovations and ...
(Date:9/19/2017)... ... September 19, 2017 , ... When it comes to household ... deserve clear instructions on how to keep babies and toddlers safe, and there's no ... Safety Month. , Great Time to Check Labels, Brands that sell all kinds of ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... TORONTO , Sept. 6, 2017 /PRNewswire/ ... new knowledge and skills while treating their ... for hands-on experience without involving patients. Simulation ... skills. Clinicians can carry out procedures, refine ... at risk. Integration of new technology, such ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology: